1. Home
  2. ARQT vs SPRY Comparison

ARQT vs SPRY Comparison

Compare ARQT & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$28.96

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$11.35

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARQT
SPRY
Founded
2016
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
1.1B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ARQT
SPRY
Price
$28.96
$11.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
4
Target Price
$24.83
$31.25
AVG Volume (30 Days)
1.8M
1.6M
Earning Date
10-28-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$317,929,000.00
$142,772,000.00
Revenue This Year
$85.51
N/A
Revenue Next Year
$30.74
$127.81
P/E Ratio
N/A
N/A
Revenue Growth
129.21
5459.66
52 Week Low
$11.13
$6.66
52 Week High
$31.77
$18.90

Technical Indicators

Market Signals
Indicator
ARQT
SPRY
Relative Strength Index (RSI) 53.65 62.09
Support Level $27.55 $9.78
Resistance Level $30.26 $11.69
Average True Range (ATR) 1.03 0.72
MACD -0.28 0.10
Stochastic Oscillator 35.15 82.21

Price Performance

Historical Comparison
ARQT
SPRY

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Share on Social Networks: